HPV vaccine: One, two, or three doses for cervical cancer prevention? - Wikidata - wikimedia - TriplyDB

HPV vaccine: One, two, or three doses for cervical cancer prevention?

HPV vaccine: One, two, or three doses for cervical cancer prevention?

http://www.wikidata.org/entity/Q36457994

about

Current status and future prospects for human papillomavirus vaccines.White, affluent, educated parents are least likely to choose HPV vaccination for their children: a cross-sectional study of the National Immunization Study - teen.Determining the HPV vaccine schedule for a HIV-infected population in sub Saharan Africa, a commentary Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact

P2860

Q40056541-267009D8-4389-412C-8D38-555CDE2221BE Q47096631-8A45684E-A0C8-4A10-8135-3928DCD9EF99 Q56987144-11598DA2-1EDE-488B-922F-22F879454DFF Q58799763-FC0C58F2-77B6-4BED-81AD-42C450D42E5A

P2860

HPV vaccine: One, two, or three doses for cervical cancer prevention?

http://www.wikidata.org/entity/Q36457994

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

HPV vaccine: One, two, or three doses for cervical cancer prevention?

@ast

HPV vaccine: One, two, or three doses for cervical cancer prevention?

@en

type

label

HPV vaccine: One, two, or three doses for cervical cancer prevention?

@ast

HPV vaccine: One, two, or three doses for cervical cancer prevention?

@en

prefLabel

HPV vaccine: One, two, or three doses for cervical cancer prevention?

@ast

HPV vaccine: One, two, or three doses for cervical cancer prevention?

@en

P1433

Q36457994-99CA39B7-ACC2-47D6-8A0B-5B7CBE66A731

P1476

Q36457994-80F312BC-9993-4B91-8D31-4406D1A0C04E

P2093

Q36457994-4363F474-9866-4C6F-8473-E5B34116A7DF

Q36457994-49D3A23B-3CAB-48D3-A895-42F9091326BC

Q36457994-80E9E0BE-A5A8-41FA-885E-295ECB8EA61A

P2860

Q36457994-09B66BDA-FE7B-4B3F-8681-9A65FD6EFD0A

Q36457994-0A89B596-9190-401D-A798-216CCC070AE7

Q36457994-0BA69E16-CC20-401F-B6E7-2A95C6010522

Q36457994-1978A274-5C2F-4A2F-839F-1C5EA727161B

Q36457994-2A5B87C4-C60A-4BFE-A29A-1B4D432EC084

Q36457994-390AA215-E8EA-416C-93C9-68F9D4179AD7

Q36457994-3D4A8F78-7F59-45CC-AE8C-DEAC0C4D7E19

Q36457994-4D37CA89-0159-4B0C-AA15-BE42FB73B8D5

Q36457994-4E6FF19E-9F3E-41F3-A28D-0C60DE2040F4

Q36457994-5F4E9FDB-153E-4B00-BC0B-F0249CD0A539

P304

Q36457994-916A8C74-64D1-4A1A-9818-212F45EE5940

P31

Q36457994-1d435096-aa42-4e7e-9011-b427cf737b03

Q36457994-689C0276-F045-4DFA-B17B-6858EE3159E0

P356

Q36457994-079A6653-0195-4432-B86D-D9A5C8CC0A1A

P433

Q36457994-930A5203-C26B-44CC-BB76-0BB38D66AD3E

P478

Q36457994-01878201-1B2D-4D1F-8C97-AED43805EB64

P577

Q36457994-ECBD6C15-33F4-4E15-8504-D34BE1969370

P698

Q36457994-C633B8E8-156B-4042-9D73-2A7CE464FAD2

P932

Q36457994-D3E6E99D-9E16-4103-83BB-211586C47788

P356

0971-5851.171534

P1433

Indian Journal of Medical and Paediatric Oncology

P1476

HPV vaccine: One, two, or three doses for cervical cancer prevention?

@en

P2093

Gauravi A Mishra

http://www.w3.org/2001/XMLSchema#string

Sharmila A Pimple

http://www.w3.org/2001/XMLSchema#string

Surendra S Shastri

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.

P304

201-206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0971-5851.171534

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26811587

http://www.w3.org/2001/XMLSchema#string

P932

4711216

http://www.w3.org/2001/XMLSchema#string